Drug intelligence / Profile preview

PF-07820435

Development stage: Phase 1
Lead developer: Pfizer
Modality: Small Molecules
Administration: Oral

Overview

PF-07820435 is an investigational, orally administered small molecule STING (stimulator of interferon genes) agonist developed by Pfizer for the treatment of solid tumors, including non-small cell lung cancer and urothelial carcinoma. The drug activates the STING pathway in immune cells within the tumor microenvironment, leading to induction of type I interferons and other pro-inflammatory cytokines. This activation enhances both innate and adaptive immune responses against tumors by increasing antigen presentation, T-cell infiltration, and promoting tumor cell death via T cell and NK cell-mediated mechanisms. PF-07820435 is currently in Phase 1 clinical trials for various solid tumors.

Other names: STING agonist PF-07820435

Targets

STING (Stimulator of interferon genes protein)

Beyond the preview

Go deeper on PF-07820435.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PF-07820435.

Explore the full profile